JP2021063129A5 - - Google Patents

Download PDF

Info

Publication number
JP2021063129A5
JP2021063129A5 JP2021003152A JP2021003152A JP2021063129A5 JP 2021063129 A5 JP2021063129 A5 JP 2021063129A5 JP 2021003152 A JP2021003152 A JP 2021003152A JP 2021003152 A JP2021003152 A JP 2021003152A JP 2021063129 A5 JP2021063129 A5 JP 2021063129A5
Authority
JP
Japan
Prior art keywords
human
seq
antibody
constant region
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021003152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021063129A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021063129A publication Critical patent/JP2021063129A/ja
Publication of JP2021063129A5 publication Critical patent/JP2021063129A5/ja
Priority to JP2023110414A priority Critical patent/JP7605914B2/ja
Priority to JP2024217195A priority patent/JP2025038055A/ja
Pending legal-status Critical Current

Links

JP2021003152A 2015-07-14 2021-01-13 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 Pending JP2021063129A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023110414A JP7605914B2 (ja) 2015-07-14 2023-07-05 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用
JP2024217195A JP2025038055A (ja) 2015-07-14 2024-12-12 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562192269P 2015-07-14 2015-07-14
US62/192,269 2015-07-14
US201562197966P 2015-07-28 2015-07-28
US62/197,966 2015-07-28
US201662277201P 2016-01-11 2016-01-11
US62/277,201 2016-01-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018521475A Division JP6826113B2 (ja) 2015-07-14 2016-07-13 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023110414A Division JP7605914B2 (ja) 2015-07-14 2023-07-05 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用

Publications (2)

Publication Number Publication Date
JP2021063129A JP2021063129A (ja) 2021-04-22
JP2021063129A5 true JP2021063129A5 (enExample) 2021-06-10

Family

ID=57757587

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018521475A Active JP6826113B2 (ja) 2015-07-14 2016-07-13 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用
JP2021003152A Pending JP2021063129A (ja) 2015-07-14 2021-01-13 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用
JP2023110414A Active JP7605914B2 (ja) 2015-07-14 2023-07-05 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用
JP2024217195A Pending JP2025038055A (ja) 2015-07-14 2024-12-12 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018521475A Active JP6826113B2 (ja) 2015-07-14 2016-07-13 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023110414A Active JP7605914B2 (ja) 2015-07-14 2023-07-05 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用
JP2024217195A Pending JP2025038055A (ja) 2015-07-14 2024-12-12 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用

Country Status (27)

Country Link
US (3) US10874738B2 (enExample)
EP (2) EP3331548B8 (enExample)
JP (4) JP6826113B2 (enExample)
KR (2) KR20250099272A (enExample)
CN (2) CN114671952A (enExample)
AU (3) AU2016294417B2 (enExample)
CL (1) CL2018000103A1 (enExample)
CO (1) CO2018001363A2 (enExample)
CR (1) CR20180097A (enExample)
DK (1) DK3331548T3 (enExample)
DO (1) DOP2018000018A (enExample)
EA (1) EA201890297A1 (enExample)
EC (1) ECSP18009949A (enExample)
ES (1) ES3075638T3 (enExample)
FI (1) FI3331548T3 (enExample)
GT (1) GT201800018A (enExample)
IL (3) IL310460A (enExample)
LT (1) LT3331548T (enExample)
MX (2) MX2018000548A (enExample)
MY (2) MY203911A (enExample)
PE (1) PE20180741A1 (enExample)
PH (1) PH12018500098A1 (enExample)
PT (1) PT3331548T (enExample)
RS (1) RS68307B1 (enExample)
SG (1) SG10201913431QA (enExample)
TN (1) TN2018000021A1 (enExample)
WO (1) WO2017011544A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913431QA (en) * 2015-07-14 2020-03-30 Immunext Inc Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
CA3006398A1 (en) 2015-11-27 2017-06-01 Ablynx Nv Polypeptides inhibiting cd40l
WO2019195770A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
WO2020056162A1 (en) * 2018-09-12 2020-03-19 Oregon Health & Science University Detecting and/or subtyping circulating hybrid cells that correlate with stage and survival
WO2020068723A1 (en) * 2018-09-24 2020-04-02 Janssen Biotech, Inc. Method of providing safe administration of an anti-cd154 antibody
CN115227824A (zh) * 2018-11-12 2022-10-25 中南大学湘雅二医院 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用
CA3136725A1 (en) * 2019-04-12 2020-10-15 Tonix Pharmaceuticals Holding Corp. Inhibitors of cd40-cd154 binding
AU2020358854B2 (en) * 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
CN113488170B (zh) * 2021-07-02 2023-07-25 温州医科大学 急性前葡萄膜炎复发风险预测模型构建方法及相关设备
WO2023008982A1 (ko) * 2021-07-30 2023-02-02 서울대학교산학협력단 항 cd154 항체 및 이의 용도
EP4382537A4 (en) * 2021-07-30 2025-07-23 Seoul Nat Univ R&Db Foundation ANTI-CD154 ANTIBODY AND ITS USE
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies
EP4703385A1 (en) * 2023-04-28 2026-03-04 Fortvita Biologics Inc. Anti-cd40l antibody and use thereof in treatment of human autoimmune diseases
US20240392022A1 (en) 2023-05-22 2024-11-28 Genzyme Corporation Treatment of multiple sclerosis with anti-cd40l antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1127351C (zh) 1993-09-02 2003-11-12 达特茅斯学院理事 诱导抗原特异性ｔ细胞耐受的方法
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6444018B1 (en) 1998-06-25 2002-09-03 Xerox Corporation Phase change ink carrier compositions containing anhydride/amino alcohol-based adducts
GB0006398D0 (en) * 2000-03-16 2000-05-03 Novartis Ag Organic compounds
NZ525793A (en) 2000-10-13 2008-04-30 Biogen Idec Inc Humanized anti-LT-beta-R antibodies
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
DK1639014T3 (da) 2003-06-13 2011-01-17 Biogen Idec Inc Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US20110123440A1 (en) 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
BRPI0809042B1 (pt) * 2007-03-22 2021-08-31 Biogen Ma Inc. Proteína de ligação a cd154 isolada, seu uso, e composição
US9321833B2 (en) * 2011-04-04 2016-04-26 The Trustees Of Dartmouth College Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
WO2012138768A2 (en) * 2011-04-04 2012-10-11 Trustees Of Dartmouth College Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies
SG10201913431QA (en) * 2015-07-14 2020-03-30 Immunext Inc Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy

Similar Documents

Publication Publication Date Title
US12116405B2 (en) Arthritis treatment
JP6096938B2 (ja) Ｉｌ−２３を結合する抗体
TWI713453B (zh) 干擾素α及ω抗體拮抗劑
CN101512008A (zh) 白介素-13结合蛋白
TW201024318A (en) Isolation and purification of antibodies using protein A affinity chromatography
JP2019525730A (ja) 抗ヒトインターロイキン−１７ａモノクローナル抗体、その製造方法及び用途
JP2023505492A5 (enExample)
TW201030016A (en) Antibodies that bind to IL-18 and methods of purifying the same
TW201031421A (en) IL-1 binding proteins
JP7783183B2 (ja) 自己免疫障害における抗ｂｃｍａ治療
CN105358575B (zh) 干扰素α和ω抗体拮抗剂
RU2016122340A (ru) Il-17a-связующий агент и способы его применения
CN110662768A (zh) 治疗性抗cd40配体抗体
US20060188505A1 (en) Treatment of autism
TW201233395A (en) Methods for treating psoriasis
US20140178388A1 (en) Multivalent antibody fragments and trimerized complexes thereof
TW202233684A (zh) 結合於葉酸受體α之重鏈抗體
US20230159632A1 (en) Anti-il-17a antibody and use thereof
WO2004004765A1 (en) Treatment of autoimmune skin diseases
TW202114734A (zh) Il-17拮抗劑治療自身免疫疾病的方法
EA050324B1 (ru) Терапия антителами против bcma при аутоиммунных расстройствах
BR122025021892A2 (pt) Células hospedeiras